Literature DB >> 26954261

Mutation screening of the PRRT2 gene for benign epilepsy with centrotemporal spikes in Chinese mainland population.

Xiang-Qian Che1, Zhan-Fang Sun1, Xiao Mao1, Kun Xia2, Xin-Xiang Yan1,2,3, Hong Jiang1,2,3, Lu Shen1,2,3, Nan Li1,2,3, Bei-Sha Tang1,2,3.   

Abstract

Proline-rich transmembrane protein 2 gene (PRRT2) mutations are reported to cause common paroxysmal neurological disorders and show a remarkable pleiotropy. Benign epilepsy with centrotemporal spikes (BECTS) is considered to be the most common epilepsy syndrome in childhood. It is placed among the idiopathic localization related epilepsies. Recently, it was reported that a girl with a PRRT2 mutation c.649_650insC developed infantile focal epilepsy with bilateral spikes which resembled the rolandic spikes. Hereby we performed a comprehensive genetic mutation screening of PRRT2 gene in a cohort of 53 sporadic BECTS patients. None of the 53 sporadic BECTS patients and other 250 controls carried mutations including c.649_650insC in PRRT2. Our data indicated that the PRRT2 mutations might most likely not be associated with BECTS in Chinese mainland population.

Entities:  

Keywords:  Chinese mainland population; PRRT2 gene; benign epilepsy with centrotemporal spikes; mutation

Mesh:

Substances:

Year:  2016        PMID: 26954261     DOI: 10.3109/00207454.2015.1136886

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  2 in total

Review 1.  Sleep Related Epilepsy and Pharmacotherapy: An Insight.

Authors:  Jaya Kumar; Amro Solaiman; Pasuk Mahakkanukrauh; Rashidi Mohamed; Srijit Das
Journal:  Front Pharmacol       Date:  2018-09-27       Impact factor: 5.810

2.  Type and etiology of pediatric epilepsy in Jordan. A multi-center study.

Authors:  Abdelkarim A Al-Qudah; Abla Albsoul-Younes; Amira T Masri; Samah K AbuRahmah; Ibrahim A Alabadi; Omar A Nafi; Lubna F Gharaibeh; Amer A Murtaja; Lina H Al-Sakran; Haya A Arabiat; Abdallah A Al-Shorman
Journal:  Neurosciences (Riyadh)       Date:  2017-10       Impact factor: 0.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.